Goldman Sachs
HOWL icon

Goldman Sachs’s Werewolf Therapeutics HOWL Stock Holding History

Goldman Sachs’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.21K Sell
20,023
-18,243
-48% -$11.1K ﹤0.01% 6488
2026
Q1 		$31.9K Buy
38,266
+4,193
+12% +$2.87K ﹤0.01% 6332
2025
Q4 		$21.6K Sell
34,073
-26,268
-44% -$31.9K ﹤0.01% 6339
2025
Q3 		$119K Sell
60,341
-167,101
-73% -$229K ﹤0.01% 6056
2025
Q2 		$248K Buy
227,442
+115,457
+103% +$119K ﹤0.01% 5550
2025
Q1 		$109K Sell
111,985
-29,845
-21% -$39.1K ﹤0.01% 5770
2024
Q4 		$210K Buy
141,830
+26,689
+23% +$54.4K ﹤0.01% 5628
2024
Q3 		$244K Buy
115,141
+63,052
+121% +$143K ﹤0.01% 5384
2024
Q2 		$127K Sell
52,089
-120,705
-70% -$580K ﹤0.01% 5369
2024
Q1 		$1.12M Buy
+172,794
New +$1.01M ﹤0.01% 4269
2022
Q3 		– Sell
-10,983
Closed -$45K – 6391
2022
Q2 		$45K Sell
10,983
-672
-6% -$3.07K ﹤0.01% 6049
2022
Q1 		$51K Buy
11,655
+1,575
+16% +$11K ﹤0.01% 6268
2021
Q4 		$120K Buy
+10,080
New +$152K ﹤0.01% 6086
2021
Q3 		– Sell
-37,435
Closed -$653K – 6340
2021
Q2 		$653K Buy
+37,435
New +$513K ﹤0.01% 5053

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs's HOWL Position: Q2 2026 in Review

Goldman Sachs reduced its Werewolf Therapeutics (HOWL) stake by 48% in Q2 2026, selling an estimated $11.1K and leaving 20,023 shares worth $7.21K. The position accounts for ﹤0.01% of the portfolio, ranked #6488.

Goldman Sachs first reported a position in HOWL in Q2 2021 and has held it in 14 quarters since. The position peaked at $1.12M in Q1 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Goldman Sachs held 20,023 shares of Werewolf Therapeutics worth $7.21K as of Q2 2026.
  • Goldman Sachs sold 18,243 Werewolf Therapeutics shares in Q2 2026, an estimated $11.1K.
  • Werewolf Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6488 holding.
  • Goldman Sachs first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • Goldman Sachs's Werewolf Therapeutics position peaked at $1.12M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.